What Is Amyloid-β? How It Accumulates in Alzheimer’s Disease

Amyloid-β in Discussions of Dementia Prevention

Dementia is no longer only a matter of individual health. It has become a major social issue affecting healthcare, long-term care, the economy, and family life. In Japan, the Basic Act on Dementia to Promote an Inclusive Society took effect in 2024¹. The law established a national approach centered on both inclusion and prevention, involving government, municipalities, and the private sector.

In research and clinical care, antibody drugs targeting amyloid-β, a protein fragment implicated in Alzheimer’s disease, have become available and are now covered by Japanese health insurance². Debate continues over their benefits and adverse effects³, increasing interest in prevention and early detection alongside pharmacological treatment.

Antibody drug

A medicine made from engineered antibodies that bind selectively to a specific substance, or antigen, in the body.

Although many people have heard the term amyloid-β, its biological role is less widely understood. This article explains what amyloid-β is, why it accumulates in the brain, how aging and lifestyle are related to its clearance, and how it interacts with another protein of growing interest: tau.

What You Will Learn

• Amyloid-β is a short peptide cut from a larger protein in the brain. When it aggregates, it can form senile plaques.
• Aggregated amyloid-β can disrupt neurons, and its accumulation may begin 20–30 years before symptoms appear.
• Alzheimer’s disease involves more than amyloid-β; tau is another major pathological protein.
• Research is examining how everyday factors may influence brain aging and waste-clearance processes.

What Is Amyloid-β?

Amyloid-β, also written as Aβ, is the collective name for short peptides cut from amyloid precursor protein (APP). When these peptides aggregate abnormally, they form insoluble deposits. Amyloid-β is the principal component of senile plaques, which are frequently observed in the brains of people with Alzheimer’s disease.

How Amyloid-β Is Produced

Amyloid-β is generated when several enzymes known as secretases cleave APP, a large protein normally present on the surface of neurons.

Under healthy conditions, APP is processed mainly through the α/γ-secretase pathway, producing shorter fragments that do not generate amyloid-β. When processing through the β/γ-secretase pathway becomes more prominent because of aging or other factors, the cell produces more amyloid-β42, or Aβ42. This 42-amino-acid form is particularly prone to aggregation. The fragments can bind together and eventually form the deposits known as senile plaques⁴.

α/γ-secretase pathway

A pathway in which α-secretase and γ-secretase cleave APP in sequence. Amyloid-β is not produced during this process, so it is often described as the non-amyloidogenic pathway.

β/γ-secretase pathway

A pathway in which β-secretase and γ-secretase cleave APP in sequence. This process releases amyloid-β. Greater activity of this pathway because of aging, genetic factors, or other influences may contribute to accumulation.

A Healthy Brain Clears Amyloid-β Continuously

Amyloid-β is produced routinely even in a healthy brain. It is normally removed rapidly through degradation systems, microglia—the brain’s immune cells—and processes including autophagy⁵, ⁶.

Accumulation Begins When Production and Clearance Fall Out of Balance

Problems arise when the balance between production and clearance is disrupted and the brain can no longer remove amyloid-β as quickly as it is produced. As clearance systems become less effective with aging, amyloid-β may accumulate in the brain over many years⁷.

Why Is Amyloid-β a Concern?

Aggregates Can Damage Neuronal Function

Aggregated amyloid-β is known to disrupt synapses, the connections between neurons, and interfere with neuronal communication⁸. Inflammation also tends to develop around aggregates and may eventually contribute to neuronal death⁹. These processes are thought to be associated with gradual declines in cognitive function, including memory and judgment.

Accumulation Begins Before Symptoms

A particularly important finding is that amyloid-β begins accumulating long before dementia symptoms become apparent.

The Dominantly Inherited Alzheimer Network, or DIAN, is an international longitudinal study of families affected by inherited Alzheimer’s disease. It reported changes in cerebrospinal-fluid amyloid-β approximately 25 years before the predicted age of symptom onset and amyloid deposition in the brain approximately 15 years before predicted onset¹⁰. By the time someone in their 40s or 50s notices increasing forgetfulness, amyloid-related changes may already have been developing for many years.

Cerebrospinal fluid

The clear fluid surrounding the brain and spinal cord. Because it reflects aspects of the brain’s internal environment, it is used in biomarker testing for neurological disorders.

This long presymptomatic period also suggests that health across the life course matters. Everyday habits may gradually influence factors associated with later brain health, although no lifestyle measure can guarantee prevention of Alzheimer’s disease.

Beyond Amyloid-β: Tau as a Second Major Pathological Protein

For many years, Alzheimer’s disease research centered on the amyloid hypothesis, which proposed amyloid-β as the primary cause of disease¹¹. However, antibody drugs that remove amyloid-β from the brain have not always produced cognitive improvements of the magnitude expected¹². Amyloid-β alone therefore does not explain the full disease process.

Current research increasingly considers multiple interacting factors, including tau, neuroinflammation, vascular factors, and lifestyle.

How Amyloid-β and Tau Differ

Amyloid-β and tau accumulate in different locations and form different pathological structures.

• Amyloid-β: Accumulates outside neurons and forms senile plaques
• Tau: Accumulates inside neurons and forms neurofibrillary tangles

Tau normally stabilizes microtubules, structural fibers within neurons. When tau becomes excessively phosphorylated, it detaches from microtubules, aggregates, and accumulates inside cells¹³.

Neurofibrillary tangles

Lesions formed when excessively phosphorylated tau aggregates inside neurons. Along with amyloid-β plaques, they are a characteristic pathological finding in Alzheimer’s disease.

Phosphorylation

The attachment of a phosphate group to a protein. This is a normal biological process, but excessive phosphorylation of tau can promote pathological aggregation.

p-tau217 as a Biomarker for Earlier Detection

Among phosphorylated forms of tau, p-tau217 is strongly associated with Alzheimer’s disease pathology and is attracting attention as a biomarker that can be measured in blood. In 2025, the United States cleared the first clinical blood test using the ratio of p-tau217 to amyloid-β42, raising the possibility of assessing Alzheimer’s-related pathology at an earlier stage¹⁴.

Advances in biomarker research may help identify pathological changes earlier and support timely clinical evaluation and intervention. A biomarker result should be interpreted by a qualified healthcare professional and is not equivalent to a diagnosis on its own.

Approaches Being Studied for Brain Health

What everyday factors may be relevant to long-term brain health? Research is examining several approaches that may influence amyloid-β and tau accumulation or support the brain’s waste-clearance processes.

High-Quality Sleep

The brain has a waste-clearance pathway known as the glymphatic system. This system is thought to become particularly active during deep sleep and to help clear amyloid-β¹⁵. Studies have also reported that sleep deprivation can be associated with higher amyloid-β concentrations in the brain. Sleep quantity and quality are therefore being studied as important components of brain health.

Glymphatic system

A lymphatic-like pathway involved in clearing metabolic waste from the brain.

Moderate Exercise

Aerobic exercise may support brain health through several pathways, including increased cerebral blood flow, modulation of autophagy, and production of brain-derived neurotrophic factor (BDNF)¹⁶. Exercise does not need to be strenuous. Regular physical activity such as walking or light jogging is associated with long-term maintenance of cognitive function¹⁷.

Diet and Nutritional Components

Research on diet includes calorie restriction and intermittent fasting, which may influence autophagy, as well as foods containing antioxidant and anti-inflammatory compounds, including green and yellow vegetables, berries, and oily fish¹⁸. Much of the mechanistic evidence remains preclinical, and effects in humans depend on the dietary pattern, population, and outcome studied.

Hexaraphane/6-MSITC, a relatively uncommon compound derived from Japanese wasabi, is known to activate the Nrf2 pathway and has reported antioxidant and anti-inflammatory effects. A randomized controlled trial in older adults reported findings in memory tests¹⁹. Research is also examining how food-derived compounds may affect abnormal tau phosphorylation. The relationship between hexaraphane/6-MSITC and tau pathology is discussed in this article.

Summary

• Amyloid-β is a short peptide cut from APP. When it aggregates abnormally, it forms senile plaques and is considered one component of Alzheimer’s disease pathology.
• Amyloid-related changes may begin 20–30 years before symptoms, making the long presymptomatic period important for research on prevention and early detection.
• Alzheimer’s disease research now considers tau alongside amyloid-β and increasingly uses a multifactorial perspective.
• Sleep, exercise, and diet are being studied as factors that may influence waste clearance, inflammation, and long-term brain health.

This article can serve as a reference whenever you want to revisit the basic question: What is amyloid-β?

References

1. 内閣府「共生社会の実現を推進するための認知症基本法」（令和5年法律第65号、2024年1月1日施行） ↩
2. エーザイ株式会社・バイオジェン・ジャパン株式会社「抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブ（製品名：レケンビ®点滴静注）の日本における保険適用について」（2023年12月20日） ↩
3. van Dyck CH, et al. "Lecanemab in Early Alzheimer's Disease." New England Journal of Medicine 388(1): 9–21 (2023) ↩
4. Haass C, Selkoe DJ. "Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide." Nature Reviews Molecular Cell Biology 8: 101–112 (2007) ↩
5. Hickman SE, et al. "Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice." Journal of Neuroscience 28(33): 8354–8360 (2008) ↩
6. Nixon RA. "The role of autophagy in neurodegenerative disease." Nature Medicine 19: 983–997 (2013) ↩
7. Mawuenyega KG, et al. "Decreased clearance of CNS β-amyloid in Alzheimer's disease." Science 330(6012): 1774 (2010) ↩
8. Selkoe DJ. "Alzheimer's disease is a synaptic failure." Science 298(5594): 789–791 (2002) ↩
9. Heneka MT, et al. "Neuroinflammation in Alzheimer's disease." Lancet Neurology 14(4): 388–405 (2015) ↩
10. Bateman RJ, et al. "Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease." New England Journal of Medicine 367: 795–804 (2012) ↩
11. Hardy J, Selkoe DJ. "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science 297(5580): 353–356 (2002) ↩
12. Nonino F, et al. "Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease." Cochrane Database of Systematic Reviews 2026, Issue 4 ↩
13. Wang Y, Mandelkow E. "Tau in physiology and pathology." Nature Reviews Neuroscience 17: 5–21 (2016) ↩
14. U.S. Food and Drug Administration. "FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease." Press Announcement (May 2025) ↩
15. Xie L, et al. "Sleep Drives Metabolite Clearance from the Adult Brain." Science 342(6156): 373–377 (2013) ↩
16. Mesrabadi J, et al. "Exercise training alters resting brain-derived neurotrophic factor concentration in older adults: A systematic review with meta-analysis of randomized-controlled trials." Ageing Research Reviews (2024) ↩
17. Livingston G, et al. "Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission." The Lancet 404(10452): 572–628 (2024) ↩
18. Mattson MP, Arumugam TV. "Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States." Cell Metabolism 27(6): 1176–1199 (2018) ↩
19. Nouchi R, et al. "Benefits of Wasabi Supplements with 6-MSITC (6-Methylsulfinyl Hexyl Isothiocyanate) on Memory Functioning in Healthy Adults Aged 60 Years and Older: Evidence from a Double-Blinded Randomized Controlled Trial." Nutrients 15(21): 4608 (2023) ↩